Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) can benefit high-risk AML patients with RUNX1-RUNX1T1 [18], although it is not generally recommended during the first complete remission (CR) [13]. Here, RUNX1T1 is linked to acute myeloid leukemia.